LY223982 is a potent P2Y7 (BLT1) receptor antagonist and benzophenone dicarboxylic acid derivative. It inhibits the specific binding of radiolabeled-LTB4 to isolated human neutrophils with an IC50 value of 13.2 nM. LY223982 inhibits the LTB4-induced aggregation of guinea pig and human neutrophils with IC50 values of 74 and 100 nM, respectively.